Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Table 5 Model results: ITT scenario analysis

Deterministic	TIO/OLO	UMEC/VI	Difference
Average number of exacerbations, per patient per life-year
Severe	0.077	0.074	−0.004
Total	0.613	0.599	−0.014
Outcomes at end of 3 years
Survival at end of time horizon	91.1%	91.4%	0.3%
Undiscounted LYs	2.885	2.889	0.003
Discounted (3% p.a.) QALYs	2.050	2.060	0.009
Costs at end of 3 years
Drug costs	€2840	€2500	−€337
Non-drug costs	€3300	€3240	−€58
Exacerbation event costs	€1080	€1030	−€48
Health state costs (by dyspnea)	€2220	€2210	−€10
Total costs	€6130	€5740	−€396
Incremental results (versus TIO/OLO)
ICER (€ per QALY gained)		Dominant
ICER (€ per LY gained)		Dominant

Cost and cost-effectiveness data are presented to three significant figures for values of four figures or more, and to the nearest Euro for values of three figures or less
ICER incremental cost-effectiveness ratio, ITT intention-to-treat, LY life years, p.a. per annum, QALY quality-adjusted life-year, TIO/OLO tiotropium/olodaterol, UMEC/VI umeclidinium/vilanterol

ISSN: 1465-993X